Dianthus Therapeutics, Inc. /DE/ DNTH

Rank #2370 · Nasdaq · $4.5B market cap

⚠ Going-concern flag — the auditor (Deloitte & Touche LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

21.7

P/E

-53.0

P/B

26.67

ROE

-50.3%

Op. Margin

-1633.7%

Debt Ratio

13%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -53.0x, P/B 26.67x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -50.3%. Ranks in the top 92% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 13%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★

Excellent

Revenue growth of 120.6% year over year. Ranks in the top 3% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2018	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-1433
2019	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-131
2020	–	$-0.1B	$-0.1B	$0.1B	–	14
2021	–	$-0.1B	$-0.1B	$0.1B	–	13
2022	–	$-0.1B	$-0.1B	$0.1B	–	12
2023	–	$-0.0B	$-0.0B	$-0.0B	–	-55
2024	$0.0B	$-0.0B	$-0.0B	$-0.0B	-1704.7	-24
2025	$0.0B	$-0.1B	$-0.1B	$0.2B	-1633.7	13

← See the full screener